Efficacy of trastuzumab re-therapy in the clinical routine of HER2-positive breast cancer patients who relapsed after completed anti-HER2 (neo)adjuvant therapy with trastuzumab – 5th interim analysis of the national non-interventional study (NIS) ML21589.

Hanker, L., Hitschold, T., Grafe, A., Förster, F., Schröder, J., Janssen, J., Reichert, D., Hielscher, C., Keitel, S., Hesse, T., 2015.

Cancer Res 76 (4 Suppl)(P4-14-08). doi:10.1158/1538-7445.SABCS15-P4-14-08

Studie: Herceptin-NIS; Indikation: Mammakarzinom; Jahr: 2015; Veranstaltung: SABCS; Journal: Cancer Research

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com